Having only revealed the existence of the biosimilar several months ago, Alvotech is aiming to be the first company to bring a biosimilar to Regeneron’s recently launched high-dose Eylea (aflibercept) 8mg formulation to global markets – a “tremendous opportunity,” the company believes, for both itself and its commercial partners Teva and Advanz Pharma.
Alvotech Aiming To Lead Competition On High-Dose Eylea Biosimilar
Icelandic Firm Manufacturing Scale-Up Batches; Follows EU Filing For Aflibercept 2mg
Regeneron’s Eylea 8mg, which offers less frequent dosing and is intended to act as a bulwark against biosimilar competition to the originator’s earlier 2mg version, is a target for biosimilar sponsor Alvotech. The Icelandic firm is aiming to lead the way in global markets.
More from Biosimilars
• By
While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
Four key areas for policy reform were identified by industry association Medicines for Europe at its biosimilars conference in early April, as sector chair Isabell Remus set out the importance of removing barriers to biosimilar competition.
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
More from Products
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.